Systemic sclerosis & Raynaud's
Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy
Authors' conclusion
We observed a sustained efficacy of selexipag on SSc digital vasculopathy during 1 year of administration.
Study context
- Population
- Patients with systemic sclerosis (SSc) with severe digital vasculopathy refractory or with contraindication to all other vasoactive therapies (63% female, mean age 50.1 years)
- Participants
- 8 patients
- Outcome
- RP and DU outcomes at 12 months
- Follow-up
- 12 months
Methodological detailssingle-group, 12-month follow-up
- Single-group
- 12-month follow-up
Main finding
As reported in the abstract
12 months
- Raynaud phenomenon (RP) daily episodes significantly decreased
- P < 0.001
- RP mean duration significantly decreased
- P = 0.01
- Complete healing of digital ulcers (DUs) in all patients within 6 months
- P = 0.03
Observational data: associations, not effects.
Further findings
Fingers skin score (modified Rodnan)
- Progressive reduction
- P = 0.03
Total digital perfusion (laser speckle contrast analysis (LASCA))
- Important increase despite seasonal variability
- P = 0.004
Capillary structure (nailfold videocapillaroscopy (NVC))
- No structural changes
Original publication
Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy. J Rheumatol. Published 15 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →